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Abstract: In the wake of the HIV epidemic, visceral
leishmaniasis (VL), a disseminated protozoan infection
caused by the Leishmania donovani complex, has been re-
emerging, particularly in North Ethiopia where up to 40%
of patients with VL are co-infected with HIV. Management
of VL in HIV co-infection is complicated by increased drug
toxicity, and high treatment failure and relapse rates with
all currently available drugs, despite initiation of antiret-
roviral treatment. Tackling L. donovani infection before
disease onset would thus be a logical approach. A screen-
and-treat approach targeting latent or the early stage of
infection has successfully been implemented in other HIV-
associated opportunistic infections. While conceptually
attractive in the context of VL–HIV, the basic understand-
ing and evidence underpinning such an approach is
currently lacking. Prospective cohort studies will have to
be conducted to quantify the risk of VL in different risk
groups and across CD4 cell count levels. This will allow
developing clinical prognostic tools, integrating clinical,
HIV and Leishmania infection markers. Interventional
studies will be needed to evaluate prophylactic or pre-
emptive treatment strategies for those at risk, ideally
relying on an oral (combination) regimen. Issues like
tolerability, emergence of resistance and drug interactions
will require due attention. The need for maintenance
therapy will have to be assessed. Based on the risk–
benefit data, VL risk cut-offs will have to be identified to
target treatment to those most likely to benefit. Such a
strategy should be complemented with early initiation of
antiretroviral treatment and other strategies to prevent
HIV and Leishmania infection.
VL–HIV Co-infection: A Globally Emerging Issue
and Major Threat in East Africa
Visceral leishmaniasis (VL), also called kala-azar, is a vector-
borne, disseminated protozoan infection caused by the Leishmania
donovani complex, predominantly affecting tissue macrophages.
Untreated, overt disease is universally lethal. The zoonotic form,
with dogs as main reservoir, is caused by Leishmania infantum and
is prevalent in several regions including the Mediterranean basin,
Central Asia and South America, with an estimated total annual
incidence of 11,000–19,000 cases/year. The anthroponotic form is
caused by L. donovani. This form is prevalent in the Indian
subcontinent and East Africa (mainly Sudan, South Sudan and
Ethiopia) with an estimated annual incidence of 190,000–370,000
cases/year [1]. HIV has been identified as one of the emerging
challenges for VL control. HIV infection dramatically increases
the risk of progression from asymptomatic Leishmania infection
towards disease (VL) and VL accelerates HIV disease progression
[2–8]. Whereas HIV has contributed to the re-emergence of VL in
Europe in the 90s, the problem of VL–HIV co-infection is now
especially marked in some regions of Ethiopia, where up to 40% of
patients with VL are co-infected with HIV [9].
Management of VL–HIV co-infection in East Africa remains
unsatisfactory [9,10]. Despite increased availability of antiretrovi-
ral treatment (ART) and more effective anti-leishmanial treat-
ment, the case-fatality rate remains high. Up to 50% of patients
fail to clear parasites from infected tissues; recurrent relapse is
frequent, ultimately leading to treatment unresponsiveness and
overwhelming parasite load [2,9–11]. It is clear that once VL is
established in HIV-infected individuals—meaning that L. dono-
vani infection has evolved to the disease stage—prognosis at the
individual level is dire, despite initiation of ART [2].
Need for an Upstream Approach: From
Prevention to Pre-emptive Treatment
Given these prevailing problems, tackling L. donovani infection
before disease onset is thus a logical approach. Similar approaches
have been successful in other HIV-associated opportunistic
infections (Table 1). Cryptococcal disease is equally associated
with poor outcomes in HIV co-infected individuals. A screen-and-
treat strategy is currently recommended by the World Health
Organization (WHO), whereby asymptomatic individuals with a
low CD4 count are systematically screened. Those testing positive
for early cryptococcal infection prior to ART initiation receive
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pre-emptive treatment with fluconazole [12,13]. However, this
strategy is underpinned by a number of facts. First, cryptococcal
antigenemia can be reliably detected, and lateral flow assays (using
blood or urine) have been developed [14]. Second, detection of
asymptomatic cryptococcal antigenemia precedes overt disease
and is an independent risk factor for mortality [13,15]. Impor-
tantly, pre-emptive treatment of asymptomatic cryptococcal
antigenemia with fluconazole can prevent clinical progression
towards overt disease and reduce mortality [16–18]. Fluconazole is
widely available within HIV programs in low-income countries,
and drug interactions with ARVs have been well studied. Isoniazid
prophylactic therapy targeting latent tuberculosis infection is
another WHO-recommended preventive strategy (Table 1). While
conceptually attractive in the context of VL–HIV co-infection, the
basic understanding and evidence underpinning such an approach
is currently lacking. Key aspects and associated knowledge gaps
relating to such a strategy are discussed in the following sections.
Targeting Asymptomatic L. donovani Infection in
HIV Co-infection
Increasingly, it has been recognized that asymptomatic Leish-
mania infections generally outnumber VL cases [19]. In some VL-
endemic East African regions, up to 20%–30% of the population
were found to be asymptomatically infected (latent infection) [20–
24]. However, how to identify asymptomatic infections is not yet
well defined [19,25]. Different markers have been used, including
serological methods, parasitological methods, urine antigen tests
and the leishmanin skin test (LST). Whether positivity in any of
these tests represents a different stage of infection over time or
whether it reflects a different parasite–host interaction and has
clinical or prognostic implications is not well known (Table 2) [19].
Asymptomatic Leishmania infection has, up to now, predom-
inantly been studied from an epidemiological perspective [19]. In
immunocompetent individuals, Leishmania infection will usually
be contained by the immune system, and treatment of asymp-
tomatic cases is currently not recommended [26]. However, the
situation might be entirely different in HIV co-infected individuals.
This group is at a substantially higher risk of progression to VL
and also faces far-reaching clinical consequences of the develop-
ment of overt VL, triggering a vicious cycle of repeated VL
episodes [2].
With the global scaling-up of ART services, there are now large
HIV patient populations living in VL-endemic East African regions
and enrolled in HIV care, although still often diagnosed with
advanced HIV disease. Until ART-induced CD4 cell count
recovery has taken place, such patients are probably at a substantial
risk of VL, and could benefit from preventive strategies. Current
data in immunocompetent individuals indicate that overt disease is
preceded by a prolonged period of asymptomatic infection, which
can be detected using different markers of Leishmania infection
[19,21]. Typically, most cases of VL occur within a year after
primary infection (usually within 6–9 months) [21], although this
period could possibly be shorter in HIV patients. Alternatively, VL
can occur due to reactivation of a previously acquired latent
infection following HIV-induced immunosuppression. Conceptual-
ly, there is an opportunity for screening strategies, integrating
markers of Leishmania infection, to capture those at high risk of VL.
Ultimately, this could lead to a screen-and-treat strategy for VL in
HIV-infected individuals living in VL-endemic areas, whereby the
Table 1. Two examples of preventive strategies against HIV-associated opportunistic infections recommended by the World
Health Organization.
Population to be screened
and aim of the strategy Marker/test
Treatment (WHO
recommended) Comments on evidence-base; perspectives
Screen-and-treat strategy for cryptococcal infection (WHO rapid advice 2010) [12]
Asymptomatic ARV naı¨ve
HIV-infected individuals
with baseline CD4 counts
,100 cells/mL before ART
initiation
Latex agglutination test for
cryptococcal antigen in
serum: technically
demanding; cost: 717
USD/test
Fluconazole 800 mg/d
for 8 weeks followed by
fluconazole 200 mg/d
until CD4 counts .200
cells/mL
Evidence base relatively limited: Retrospective observational
studies on natural evolution of asymptomatic cryptococcal
antigenemia and risk of progression (according to CD4 cell
counts)
To target early, active
cryptococcal infection to
prevent progression to overt
cryptococcal disease;
(meningitis is associated with
high mortality)
Prototype dipstick
developed (point of care):
for serum/urine: cost: 2.5
USD/test
- Widely available in
HIV treatment programs
(donation program)
Treatment: small retrospective/prospective observational
studies; no randomized controlled trials; optimal fluconazole
dose to be determined; ARV drug interactions & safety
relatively well studied
Isoniazid prophylactic therapy - IPT (WHO guidelines, 2009)
[76]
HIV-infected individuals,
irrespective of ART use,
with active tuberculosis (TB)
ruled out
Tuberculosis skin test Isoniazid prophylactic
treatment (IPT) 300 mg/d
for 6 months; Longer duration
if high TB transmission: effect
weans off after IPT interruption
Strong evidence base
To prevent reactivation
of latent
- Requires patient to
return after 72 hours
- Widely available in a TB & HIV
programs (low cost)
- Prospective observational studies
to identify risk and risk markers
TB infection (and possibly
also reinfection)
- IPT indicated if skin
test positive
- Interventional studies on IPT- ARV
drug interactions & safety relatively well studied
- If skin test not available,
treatment for all
Interferon-c release assays to target IPT
Shorter regimens under evaluation
ARV: antiretrovirals; ART: antiretroviral treatment; WHO: World Health Organization.
doi:10.1371/journal.pntd.0003011.t001
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individual’s short-term risk of VL is assessed at every clinical
encounter. However, several knowledge gaps will need to be
addressed before this strategy can be taken forward to implemen-
tation in resource-limited VL-endemic areas.
Developing prognostic clinical tools
The development of clinical tools to predict the risk of VL in
HIV-infected individuals would be a prerequisite for an effective
screen-and-treat approach. Such prognostic models, relying on
Table 2. Direct and indirect markers of Leishmania infection and their features.
Features and clinical/epidemiological significance Knowledge gaps; operational issues and challenges
Direct
PCR on peripheral blood
Presumed recent circulation of viable parasites No detailed studies in HIV-infected patients of kinetics of
PCR prior to VL
Asymptomatic & immunocompetent: no clinical
significance; epidemiological marker of VL exposure
Challenging to implement in resource-constrained settings
Diseased individuals: diagnosis and post-treatment monitoring - cost; technically demanding; LAMP in development
Quantitative thresholds associated with risk of disease
progression
- ideally: in dipstick format and semi-quantitative
Microscopy and culture
(peripheral blood)
Circulation of (viable) parasites Few studies in asymptomatic patients, sensitivity probably
very low in asymptomatic infection
Microscopy on peripheral blood (Giemsa staining) Leucocyte concentration methods to increase sensitivity
under exploration
Conventional culture (several weeks; technically demanding) Microculture: more sensitive/faster (but not same-day result)
Microculture methods: culture in microtiter plates,
reading with inverted microscope
Latex agglutination test
(urine antigen)
Renal excretion of parasite antigen No data on asymptomatic infection: sensitivity possibly low
Source unclear: peripheral blood? Renal? Cost ,2$/test; next generation assay in development:
potential for semi-quantitative dip-stick format;
Semi-quantitative test (minimal equipment required
(boiling step))
Indirect
Direct agglutination test
(DAT); (serology)
Seroconversion: risk factor for VL; epidemiological
marker of recent exposure
Feasible in field setting but requires overnight incubation
Cost ,2$/test
Possibly amendable to dip-stick format;
rK39 ELISA or RDT (serology)
Seroconversion: risk factor for VL; epidemiological
marker of recent exposure
No data on asymptomatic infection in HIV
ELISA titer associated with treatment response/relapse; Other serological tests not readily available in RCS
RDT: cost ,1$/test
Leishmanin skin test (LST)
Measures delayed hypersensitivity response
(reading after 72 hours)
Delayed responses (in general) can be reduced by
immunodeficiency (cfr TB); cost ,2$/test
Measure of protection against VL Requires follow-up visit after 72 hours; limited production
Mainly used for epidemiological purpose (past exposure)
Interferon-release assays
(IGRAs)
Detects T-cells in peripheral blood reactive to
Leishmania antigens
Technically demanding but same day result possible, high
cost
Positive response in active disease and asymptomatic infection Possibly less affected by immunodeficiency (cfr TB)
ELISA: enzyme-linked immunosorbant assay; LAMP: Loop-mediated isothermal amplification; PCR: polymerase chain reaction; RCS: resource-constrained settings; RDT:
rapid diagnostic test; TB: tuberculosis; VL: visceral leishmaniasis.
doi:10.1371/journal.pntd.0003011.t002
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simple clinical and laboratory data, have, for instance, been
developed to predict the one-year-term mortality in HIV-infected
individuals starting ART, with predicted mortality ranging from
below 1% to up to 60% [27]. Likewise, VL prognostic clinical tools
could be developed, including clinical information, HIV-related
laboratory information (CD4 count) and leishmanial markers. In
more complex models, immunological markers and other more
advanced biomarkers could be integrated.
Direct leishmanial markers. Leishmanial markers either
directly detect the parasite or its components, or indirectly detect
the immunological reaction against the parasite (Table 2).
Amongst the direct markers, molecular tests like the polymerase
chain reaction (PCR) are increasingly used. PCR positivity for
Leishmania on peripheral blood, probably indicating recent
circulation of viable parasites, has been found very commonly in
VL-endemic regions [19,20,28]. The kinetics of PCR-positivity in
relation to asymptomatic Leishmania infection has, however, not
been studied in detail in the immunocompetent nor immunode-
ficient population. Whether this is short-lived or chronic/
intermittent with fluctuating levels and whether this has prognostic
implications is not yet well-defined [29–31].
PCR (on bone marrow and peripheral blood) has been used as a
tool to diagnose VL, monitor treatment response and predict
relapse in HIV-infected individuals [32,33]. With quantitative
PCR, thresholds could be identified, predicting the onset of
symptoms and progression to disease (VL relapse). However, its
value as a screening tool for asymptomatic Leishmania infection in
HIV-infected individuals has not been evaluated so far. A single
study in Brazil (where L. infantum is prevalent) found a high
prevalence of PCR-positivity in HIV patients enrolled in HIV
care. The risk of progression to VL in a population with good
access to ART appeared to be low [34]. However, this could be
entirely different with L. donovani and in populations where
access to HIV care is delayed, and co-infections and malnutrition
are common. Possibly, repeated positivity or increasing PCR levels
in an HIV-infected individual could herald the onset of VL. A
(semi-quantitative) dipstick format with different thresholds would
be required for field implementation.
Commercially available latex agglutination tests to detect
Leishmania urine antigen have been explored in Europe in
HIV-infected individuals with VL (Table 2) [35]. Whereas
repeated antigen positivity was predictive of subsequent relapse,
its value as a prognostic marker to predict the onset of VL (i.e.,
prior to the onset of VL) remains to be determined. For diagnostic
purposes, it was found highly specific but insufficiently sensitive,
including in East Africa [36]. However, improved tests are in
development. The recent development of point-of-care urine
antigen tests for tuberculosis and cryptococcal infection can serve
as inspiring examples [14,37].
Other methods, like microscopy or conventional culture on
peripheral blood, are unlikely to be sufficiently sensitive in
asymptomatic infections in the current format [38,39]. Micro-
culture methods on peripheral blood might possibly be more
sensitive [38,40].
Humoral and cellular immune response markers.
Amongst the different diagnostic serological tests, the direct
agglutination test (DAT) and rK39 rapid diagnostic test (RDT), or
ELISA, are most commonly used in resource-limited settings
(Table 2). DAT sero-conversion has been identified as a risk factor
for VL in the Indian subcontinent and in East Africa [21,41]. In a
recent study, high titer DAT converters had a 100-fold increased
risk of VL, reaching up to 12% [42]. Serological responses in
asymptomatic infection can be transient and sero-reversion can
occur [41]. Of interest, in an Ethiopian study where six-monthly
DAT testing was done, recent sero-converters comprised over
90% of VL cases, with around 10% of recent sero-converters
subsequently progressing to VL [21]. There are, however, no
studies from East Africa specifically focussing on HIV-infected
individuals.
There is some evidence supporting rK39 ELISA as a prognostic
marker for VL in immunocompetent individuals in Brazil [43] and
India [44]. In the latter study, positivity on rK39 testing in
contacts of VL cases was found to have predictive values of 44%
and 69% for the occurrence of VL over the next 3 and 12 months
respectively. There are, however, indications that the antibody
response is attenuated in HIV-infected individuals [45]. The
antibody response in HIV-infected patients might also depend on
whether Leishmania infection precedes HIV infection or vice
versa. A few small studies from Europe nevertheless provide
support for serology—including DAT—as a marker predictive of
VL in HIV patients [46,47].
The LST has been mostly used for epidemiological purposes
(Table 2) [21,23,24,48]. A positive LST has consistently been
shown to be a reliable indicator of protective immunity [21,48–
50]. How HIV infection impacts LST positivity has not been well
studied. Similarly, as for tuberculosis, prototype interferon-c
release assays have been developed recently [51]. Their exact
value to detect asymptomatic Leishmania infection, especially in
immunocompromised individuals, remains to be determined.
Besides Leishmania-related factors, HIV infection markers (e.g.,
CD4 count, inflammation markers, HIV-1 viral load) should be
evaluated as well. Several cytokines have also been explored as
prognostic markers, and a range of other immunological markers
(e.g., macrophage activation markers) merit consideration [52–
60]. Amongst the cytokines, interleukin-10 looks most promising
but has not been studied specifically in HIV-infected individuals
[61]. Broad-based genetic analysis (post-genomic methods) might
provide new leads [62,63]. For instance for tuberculosis, this has
allowed discrimination (‘‘biosignatures’’) of uninfected versus
latently infected versus diseased individuals [64,65]. Although
such complex methodologies should initially be evaluated in
research environments, promising leads might subsequently be
amenable to simplification and adaptation to resource-constrained
settings [65].
Drugs for preventive therapy
Choices will have to be made regarding which drugs to assess in
clinical VL prevention studies, which may obviously vary across
settings and regions. All main drugs currently used to treat VL
have a number of limitations (Table 3) [1]. In areas with zoonotic
transmission, parenteral administration (every 3–4 weeks) of
pentavalent antimonials, lipid formulations of amphotericin B or
pentamidine has been recommended for secondary prophylaxis
after patent VL in patients at risk of relapse [26,66].
Ideally, drugs that currently form the backbone of VL treatment
programs should not be used for preventive therapy in anthro-
ponotic VL regions (East Africa and the Indian subcontinent),
given the potential risk of emergence and spread of drug resistant
parasites [24]. However, this argument is relative, since avoiding
treatment of multiple poorly responsive VL episodes might also
constitute a resistance prevention strategy. Monthly intravenous
administration of pentamidine—not a first line drug—is currently
under evaluation in Ethiopia (NCT01360762) for individuals at
high risk of VL relapse (i.e., secondary prophylaxis). However, it is
unclear whether VL preventive strategies relying on repeated
parenteral administration of anti-leishmanial drugs will look
favourable in terms of cost and risk benefit. Most likely, the risk
of progression to VL amongst those likely to benefit from
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preventive strategies will be lower than the risk of VL relapse (up
to 60% by one year) once VL has been established.
Ideally, preventive therapy should be oral, well tolerated, and
cheap, similarly as fluconazole for cryptococcal disease, isoniazid
for tuberculosis, or co-trimoxazole for toxoplasmosis. Combina-
tion therapy might be indicated to shorten treatment and lessen
the risk of emergence of drug resistance, or to enhance the efficacy
of two moderately active oral drugs [67]. Miltefosine is the only
oral drug available, but has substantial gastro-intestinal intoler-
ance, and adherence is often poor (Table 3). Its long half-life and
low genetic barrier facilitate the emergence of drug resistance [1].
Miltefosine has been successfully used as maintenance therapy in
HIV-infected individuals, in monotherapy, or combined with
itraconazole [68]. Fluconazole (combined with allopurinol) and
itraconazole were also effective as maintenance therapy in a few
case series of immunosuppressed patients [69–71].
A number of novel oral drugs are in development. Imipramine,
a commonly used oral drug against depression, is readily available,
well tolerated, and highly effective in animal models [72]. Similar
drugs (e.g., amitriptyline) are often used in HIV care programs in
low-income countries to treat neuropathic pain and depression.
Such drugs could also be taken for an extended duration, as
preventive treatment. Data on clinical efficacy against VL are
currently lacking. Fexinidazole is undergoing clinical evaluation
[73]. Several other new chemical entities are in development by
the Drugs for Neglected Diseases initiative and others [74].
In Europe, there have been indications that parasites found
during asymptomatic infection differ from those found during
disease [75]. Moreover, parasites causing VL in HIV-infected
individuals have been found to be more diverse, with higher
enzymatic polymorphism, compared to the general population [2].
There are currently no data whether parasites causing latent
infection are susceptible and accessible to anti-leishmanial drugs,
let alone in HIV co-infected individuals in East Africa.
Treatment strategies
In line with other opportunistic infections, preventive treatment
strategies could be broadly divided in two categories [66].
Primary prophylaxis (prophylactic therapy) would mainly aim at
preventing Leishmania infection, or target latent infection, perhaps
as indicated by sero-conversion of Leishmania serological tests.
Such a strategy could possibly be of value with moderate
immunosuppression (e.g., CD4 counts of 200–350 cells/mL).
Isoniazid preventive therapy targeting latent tuberculosis infection
would be the prototype example (Table 1) [76]. A CD4-guided
approach, as used with co-trimoxazole primary prophylaxis, would
be an alternative simple approach [77]. Such a strategy would
particularly be indicated if progression from asymptomatic
infection to disease would be found to be too short to be captured
during screening.
Pre-emptive therapy would essentially aim at blocking VL
progression at an early stage, following detection of parasite
replication (e.g., as evidenced by detection of urine antigen and/or
a specific pattern or level of PCR positivity) prior to symptom
onset. Possibly, this strategy might be indicated for severe
immunosuppression (e.g., CD4 counts ,100 cells/mL). Screening
for cryptococcal antigen in asymptomatic HIV-infected patients at
risk (low CD4 cell counts), followed by pre-emptive therapy to
block progression to cryptococcal meningitis is a well-known
example [13].
A short course of prophylactic or pre-emptive therapy could be
effective under the assumption that all parasites can be cleared
from the body. In light of the prevailing dogma that sterile cure is
not achievable with treatment, this scenario is unlikely [78]. A
more likely outcome is that the parasite load would be reduced
significantly (‘‘pulse therapy’’), so as to reduce the short-term risk
of VL. In this scenario, maintenance therapy or repeated
treatment cycles might still be indicated to suppress parasite
replication until sufficient ART-induced immune recovery has
taken place. This would possibly also protect against reinfection,
in the event of ongoing Leishmania exposure. For most HIV-
associated opportunistic infections, prolonged prophylaxis or
maintenance therapy has been found necessary to prevent
reinfection and/or reactivation [66]. The recommended duration
and/or CD4 threshold to discontinue preventive therapy will also
have to be defined. However, there are currently no studies
detailing how the risk of VL due to L. donovani (in East Africa)
Key Learning Points
N Management of VL in HIV co-infection is complicated
with high case fatality and relapse, warranting preven-
tive strategies.
N A screen-and-treat approach targeting latent or the early
stage of infection has successfully been implemented in
other HIV-associated opportunistic infections.
N The basic understanding and evidence underpinning
such an approach against VL in HIV coinfection is
currently lacking; there are no validated markers for
asymptomatic infection.
N Prospective cohort studies are required to quantify the
risk of VL in different risk groups and across CD4 cell
count levels.
N Interventional studies are needed to evaluate prophy-
lactic or pre-emptive treatment strategies for those at
risk, ideally relying on an oral (combination) regimen.
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relates to CD4 cell count values and stages of immune
suppression.
Conclusions and Perspectives
Preventive treatment strategies have been explored and
successfully implemented for all major HIV-associated opportu-
nistic infections, following carefully conducted observational and
interventional studies [66]. Given the poor treatment response of
VL in HIV co-infected patients, even with ART, such strategies
merit exploration.
A number of research gaps need to be filled (Key Learning
Points). First, prospective cohort studies will have to be conducted
to allow developing prognostic models, quantifying the risk of
disease progression in different risk groups and across CD4 cell
count levels. Subsequently, interventional studies will be needed to
evaluate prophylactic or pre-emptive treatment strategies, ideally
relying on an oral (combination) regimen. Careful evaluation of
tolerability will be required, since increased toxicity has been
observed with several anti-leishmanial drugs used to treat VL in
patients with HIV co-infection. Nonetheless, the drugs are likely to
be better tolerated in patients with less advanced HIV infection.
Adherence to oral VL drugs, which has been cumbersome in VL
patients, might be even more problematic in asymptomatic
individuals. Based on the risk–benefit data, VL risk cut-offs will
have to be identified at the local level to target treatment to those
most likely to benefit.
A screen-and-treat strategy should be complemented by early
ART initiation, as now recommended by WHO [79]. The decline
in incidence of VL–HIV co-infection in Europe following the
introduction of ART is a powerful testimony of the effectiveness of
that strategy. However, in many settings, HIV is still detected at an
advanced stage of immunosuppression, meaning individuals will
remain at risk for an extended period before sufficient immune
recovery has occurred. Additional efforts engendering early HIV
detection are warranted.
Besides improved diagnosis and treatment of diseased individ-
uals, a screen-and-treat approach to prevent VL could be a
complementary strategy to decrease the burden of VL–HIV co-
infection. In the process, issues like ARV drug interactions [80]
and the potential emergence of drug resistant parasites will have to
be evaluated, besides cost-effectiveness assessments. Since pre-
venting the onset of VL also prevents the potential downstream
consequences—including multiple relapses—targeted preventive
efforts might be highly cost-effective. Other strategies to prevent
HIV and Leishmania infection should be considered in parallel.
In conclusion, although a screen-and-treat approach strategy is
conceptually attractive for resource-constrained settings with a
high VL–HIV burden, the evidence base is currently lacking.
Carefully conducted studies will be required to define its safety,
feasibility and effectiveness. Such a strategy might also be valuable
for other immunosuppressive conditions, currently most prevalent
in high-income countries.
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